At a glance
ClinicalIndex Comparison RecordN/ACompleted· 765 enrolled
Drug / intervention
Concomitant Bevacizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Cohort Survey of Patients With Metastatic Colorectal Cancer Starting a Chemotherapy in Combination With Avastin®
In Brief
An observational study evaluating Observational Chemotherapy and Concomitant Bevacizumab for Metastatic Colorectal Cancer. Completed, enrolled 765 participants across 1 site.
Detailed Summary
This is a longitudinal, multicenter, prospective, pharmacoepidemiological study to evaluate progression free survival (PFS) in a real-life setting in participants with metastatic colorectal cancer (mCRC) starting chemotherapy combined with bevacizumab.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Colorectal Cancer
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
Primary CompletionOct 2012
First PostedNov 2015
TodayJul 2026
First PostedNov 23, 2015
Enrollment StartMay 1, 2008
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.6 years ago
Interventions
Observational Chemotherapyother
No intervention - Observational standard practice chemotherapy
Concomitant Bevacizumabdrug
No intervention - Observational concomitant bevacizumab